dextrothyroxine has been researched along with Hypoxia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borody, TJ; Clancy, RL; Dave, S; Dolai, S; Gunaratne, AW; Hazan, S; McCullough, PA | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE | 1 |
| Anderson, B; Avula, N; Belani, HK; Biros, M; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Fricton, R; Hagen, AA; Hartman, KM; Huling, JD; Ingraham, NE; Karger, AB; Klatt, NR; Lee, S; Liebovitz, DM; Lindberg, S; Luke, DG; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, MF; Puskarich, MA; Rao, V; Reddy, NV; Saveraid, HG; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Tordsen, WJ; Zaman, A | 1 |
| Garza-Santiago, E; Kammar-García, A; Mancilla-Galindo, J; Ortiz-Hernández, A | 1 |
| Depping, R; Kluxen, L; Kosyna, FK; Kraushaar, K; Nagel, M | 1 |
1 trial(s) available for dextrothyroxine and Hypoxia
| Article | Year |
|---|---|
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind Method; Female; Fluvoxamine; Humans; Hypoxia; Ivermectin; Male; Metformin; Middle Aged; Obesity; Overweight; Pregnancy; Pregnancy Complications, Infectious; SARS-CoV-2 | 2022 |
4 other study(ies) available for dextrothyroxine and Hypoxia
| Article | Year |
|---|---|
Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.
Topics: COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hypoxia; Ivermectin; Leprostatic Agents; SARS-CoV-2; Treatment Outcome | 2022 |
Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysauto-nomia.
Topics: Animals; Bees; COVID-19; gamma-Aminobutyric Acid; Humans; Hypoxia; Ivermectin; Primary Dysautonomias; SARS-CoV-2 | 2022 |
Comment on: 'Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients'.
Topics: COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hypoxia; Ivermectin; Leprostatic Agents; SARS-CoV-2 | 2022 |
The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways.
Topics: beta Karyopherins; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Ivermectin; Microscopy, Fluorescence; Protein Binding; Real-Time Polymerase Chain Reaction; Signal Transduction | 2015 |